Everolimus, an mTOR inhibitor, has been reported in a phase II trial to show antitumor activity in advanced MTC with the main toxicities being mucositis, fatigue and hypertriglyceridemia.33 Here, MTOR is linked to medullary thyroid gland carcinoma.